Dr. Robert Driscoll
Recent Articles about Replimune Group Inc.
MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA 05/06/2026
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma.
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
